| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
19,740,000 |
| Market
Cap: |
4.17(B) |
| Last
Volume: |
9,322,967 |
Avg
Vol: |
9,297,189 |
| 52
Week Range: |
$120.4 - $292.92 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 27 |
| Insider 3/6 Months : 27.6 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Co.'s primary product candidate, resmetirom, is being developed as a once-daily oral pill to treat several disease states, including non-alcoholic steatohepatitis, or NASH. Co. has initiated MAESTRO-NASH, a Phase 3 trial in NASH with its once daily, oral thyroid hormone receptor beta selective agonist, resmetirom. Co. has opened for enrollment MAESTRO-NAFLD-1, a Phase 3 clinical study of patients with biopsy-confirmed or presumed NASH recruited from sites in the U.S.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
424,685 |
424,685 |
424,685 |
| Total Buy Value |
$0 |
$77,751,391 |
$77,751,391 |
$77,751,391 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
10 |
10 |
10 |
| Total Shares Sold |
252,542 |
270,142 |
270,142 |
339,631 |
| Total Sell Value |
$62,399,106 |
$66,219,580 |
$66,219,580 |
$85,688,008 |
| Total People Sold |
5 |
7 |
7 |
8 |
| Total Sell Transactions |
13 |
21 |
21 |
26 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bahcall Safi R |
President and CEO |
• • – |
2013-06-28 |
4 |
B |
$5.03 |
$50,299 |
D/D |
10,000 |
2,033,135 |
2.81 |
- |
|
| Kovner Bruce |
Director |
– • • |
2013-06-27 |
4 |
B |
$4.71 |
$706,515 |
I/I |
150,000 |
3,100,000 |
2.25 |
- |
|
| Kovner Bruce |
Director |
– • • |
2013-06-26 |
4 |
B |
$4.65 |
$1,395,930 |
I/I |
300,000 |
2,950,000 |
2.25 |
- |
|
| Kovner Bruce |
Director |
– • • |
2013-06-25 |
4 |
B |
$4.35 |
$869,460 |
I/I |
200,000 |
2,650,000 |
2.25 |
- |
|
| Kovner Bruce |
Director |
– • • |
2013-06-24 |
4 |
B |
$4.43 |
$885,920 |
I/I |
200,000 |
2,450,000 |
2.25 |
- |
|
| Kovner Bruce |
Director |
– • • |
2013-06-21 |
4 |
B |
$4.23 |
$211,520 |
I/I |
50,000 |
2,250,000 |
2.25 |
- |
|
| Bahcall Safi R |
President and CEO |
• • – |
2013-06-21 |
4 |
B |
$4.12 |
$82,374 |
D/D |
20,000 |
2,023,135 |
2.81 |
- |
|
| Kovner Bruce |
Director |
– • • |
2013-06-18 |
4 |
B |
$4.00 |
$799,160 |
I/I |
200,000 |
2,200,000 |
2.25 |
- |
|
| Bahcall Safi R |
President and CEO |
• • – |
2013-06-14 |
4 |
B |
$4.06 |
$40,550 |
D/D |
10,000 |
2,003,135 |
2.81 |
- |
|
| Bahcall Safi R |
President and CEO |
• • – |
2013-06-06 |
4 |
B |
$4.04 |
$40,390 |
D/D |
10,000 |
1,993,135 |
2.81 |
- |
|
| Kovner Bruce |
Director |
– • • |
2013-06-06 |
4 |
B |
$4.31 |
$3,186,950 |
I/I |
738,900 |
2,000,000 |
2.25 |
- |
|
| Kovner Bruce |
Director |
– • • |
2013-06-05 |
4 |
B |
$4.71 |
$3,561,743 |
I/I |
756,000 |
1,261,100 |
2.25 |
- |
|
| Vukovic Vojo |
SVP, Chief Medical Officer |
• – – |
2013-06-05 |
4 |
B |
$4.58 |
$45,800 |
D/D |
10,000 |
35,249 |
2.74 |
- |
|
| Kovner Bruce |
Director |
– • • |
2013-06-04 |
4 |
B |
$4.99 |
$2,521,661 |
I/I |
505,100 |
505,100 |
2.25 |
- |
|
| Wilson Robert N |
Director |
– • – |
2013-06-04 |
4 |
B |
$5.00 |
$50,000 |
D/D |
10,000 |
699,679 |
2.39 |
- |
|
| Bahcall Safi R |
President and CEO |
• • – |
2013-05-08 |
5 |
GA |
$0.00 |
$0 |
I/I |
200,000 |
100,000 |
|
- |
|
| Bahcall Safi R |
President and CEO |
• • – |
2013-05-08 |
5 |
GD |
$0.00 |
$0 |
D/D |
200,000 |
1,853,135 |
|
- |
|
| Ramachandra Sumant |
President, R&D |
• – – |
2013-03-11 |
4 |
A |
$0.00 |
$8 |
D/D |
75,000 |
75,000 |
|
- |
|
| Gollust Keith R |
Director |
– • – |
2013-01-23 |
4 |
OE |
$2.38 |
$989,603 |
D/D |
114,250 |
316,255 |
|
- |
|
| Bahcall Safi R |
President and CEO |
• • – |
2013-01-04 |
5 |
GA |
$0.00 |
$0 |
I/I |
65,000 |
65,000 |
|
- |
|
| Bahcall Safi R |
President and CEO |
• • – |
2013-01-04 |
5 |
GD |
$0.00 |
$0 |
I/I |
65,000 |
0 |
|
- |
|
| Gollust Keith R |
Director |
– • – |
2012-12-12 |
4 |
A |
$8.60 |
$2,150,000 |
I/I |
250,000 |
175,000 |
|
- |
|
| Bahcall Safi R |
President and CEO |
• • – |
2012-12-12 |
4 |
A |
$8.60 |
$86,000 |
D/D |
10,000 |
2,383,135 |
|
- |
|
| Wilson Robert N |
Director |
– • – |
2012-12-12 |
4 |
A |
$8.60 |
$500,004 |
D/D |
58,140 |
689,679 |
|
- |
|
| Kufe Donald W |
Director |
– • – |
2012-12-12 |
4 |
A |
$8.60 |
$50,000 |
D/D |
5,814 |
17,748 |
|
- |
|
413 Records found
|
|
Page 9 of 17 |
|
|
6.07 (2.96%) 
